'Hepatitis C - Small-Molecule Antivirals Pave the Way for Triple Therapy' Report Available Now
Posted on: Thursday, 7 February 2008, 09:01 CST
Research and Markets (http://www.researchandmarkets.com/reports/c82079) has announced the addition of "Stakeholder Opinions: Hepatitis C - Small-Molecule Antivirals Pave the Way for Triple Therapy" to their offering.
Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited efficacy in other patients offer much room for improvement. Several development setbacks over the past 18 months highlight the obstacles in R&D.
Scope
- In-depth analysis of hepatitis C patient potential and dynamics across the major Western markets
- Thorough assessment of unmet needs and shortfalls of current HCV therapy
- Review of current clinical trial practice and key drug classes in development for hepatitis C
- In-depth discussion of novel hepatitis C pipeline candidates and assessment of their potential in HCV therapy
Highlights of this title
Due to the suboptimal efficacy and safety profile of current standard HCV therapy, there is a large unmet need for drugs with an improved clinical profile. Experts agree that add-on therapy currently seems more promising than interferon or ribavirin replacement approaches.
Recent clinical data on small-molecule polymerase and protease inhibitors has sparked high hopes for improving SVR rates through triple therapy. Vertexs telaprevir, Schering Ploughs boceprevir and Roches R-1626 currently show the most promising profiles.
Further strategies in HCV drug development include host enzyme inhibitors and non-interferon immunomodulators. However, although theoretically highly promising, most candidates are in very early stages of development and not expected to reach the market soon.
Key reasons to purchase this title
- Review the epidemiological and clinical factors driving new product decisions in hepatitis C as well as unmet needs with current treatment options.
- Gain insight through a detailed discussion of key pipeline candidates in late-stage development for hepatitis C.
- Understand where concerns and future opportunities lie by learning about the views of key hepatitis B opinion leaders.
Content Outline:
ABOUT US HEALTHCARE
About the Infectious Diseases pharmaceutical analysis team
Chapter 1 Executive Summary
Chapter 2 Disease Background And Current Treatment
Chapter 3 Patient Potential
Chapter 4 R&D Approach
Chapter 5 Interferons
Chapter 6 Small Molecule Antivirals
Chapter 7 Immunomodulators (Non-Interferon)
Chapter 8 Host Enzyme Inhibitors
Appendix A
Appendix B
List of Tables
List of Figures
Companies Mentioned:
- Biotest AG
- Boehringer Ingelheim GmbH
- CDC SPA
- Centerline Holding Company
- Flamel Technologies
- Friedman Industries
- Group 1 Automotive, Inc.
- HCC Insurance Holdings, Inc.
- Human Genome Sciences Inc.
- Idenix Pharmaceuticals, Inc.
- Insight Communications Company, Inc.
- Kirin Brewery Holdings Company, Limited
- Maersk Logistics
- Mochida Pharmaceutical Co., Ltd.
- Nabi Biopharmaceuticals
- Novartis AG
- Omega Protein Corporation
- Safety Insurance Group, Inc.
- Saul Centers, Inc.
- Schering-Plough Corporation
- Vertex Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/reports/c82079
Source: Datamonitor
Source: Business Wire
Related Articles
- New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
- ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
- Patient Advocacy Is the Focus of December's Current Clinical Practice
- Hospitalists and the Future of Medical Training Are the Focus of October's Current Clinical Practice
- Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
- U.S. Army Selects Cogon Systems to Develop Advanced Clinical Decision Support Tools for Hand Held Computers
- GTC Biotherapeutics Enters into Process Development and Clinical Supply Manufacturing Services Agreement With PharmAthene for Protexia(R)
- Dynavax Initiates Phase I Trial of Hepatitis B Therapy
- Pegasys(R) Findings Suggest New Approaches to Maximize Hepatitis C Therapy
- Roche and Pharmasset Join Forces to Develop New Generation of Hepatitis C Therapies
 |
 |
User Comments (0)
RSS Feeds